Immunohistochemistry (IHC) staining of residual tumor specimens demonstrated increased YAP nuclear levels in residual tumor cells present at the treatment endpoint in both PDX and CDX models (Fig. 4d, e, Supplementary Fig. 8c). Here, YAP1 is linked to neoplasm.